A Trial of HRS-9813 Capsule and Tablet in Healthy Subjects

Evaluation of the Relative Bioavailability of HRS-9813 Capsule and Tablet in Healthy Subjects and the Effect of Food on the Pharmacokinetics of HRS-9813 Capsule

This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.

Inclusion Criteria:

1. Aged 18-45 years.
2. Male weight ≥ 50 kg, female weight ≥ 45 kg, and body mass index (BMI): 19-26 kg/m2.
3. Subjects not with clinically significant vital signs and laboratory tests.
4. Take contraception measures.

Exclusion Criteria:

1. Any serious clinical diseases that affect the absorption, metabolism and/or excretion of the study drug.
2. Severe infection, severe trauma or major surgery.
3. Any medications in the two weeks before screening or baseline period.
4. History of blood donation or severe blood loss.
5. Have been vaccinated within 2 weeks before the screening or baseline period.
6. History of smoking or excessive alcohol or drug abuse.
7. Other situations that the researcher judges to be unsuitable.